IRX 4204

Drug Profile

IRX 4204

Alternative Names: AGN-194204; ALRT-4204; IRX-4204; NRX-194204; NRX-4204; VTP-194204

Latest Information Update: 16 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergan
  • Developer Icahn School of Medicine at Mount Sinai; Io Therapeutics
  • Class Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Immunomodulators; Nuclear receptor subfamily 4 group A member 2 agonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I Non-small cell lung cancer; Parkinson's disease
  • Preclinical Alzheimer's disease; Multiple sclerosis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 14 Sep 2016 Preclinical pharmacodynamics data in Multiple sclerosis presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
  • 01 May 2016 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Combination therapy, Recurrent, Second-line therapy or greater) in USA (PO) (NCT02991651)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top